Abstract:Purpose To validate the feasibility and efficacy of intratumoral radiofrequency hyperthermia (RFH)-enhanced herpes simplex virus (HSV) thymidine kinase (TK) and ganciclovir (GCV) (hereafter, HSV-TK/GCV) gene therapy for non-small-cell lung cancer (NSCLC). Materials and Methods This study was performed from November 11, 2015, to April 14, 2017, and included (a) in vitro experiments with human NSCLC cells to establish the proof of principle, (b) in vivo experiments using mice with subcutaneous NSCLC to further demonstrate the principle, and (c) in vivo experiments using rats with orthotopic NSCLC to validate the technical feasibility. Cells, nude mice, and nude rats were randomly divided into four groups (six animals per group): (a) combination therapy (HSV-TK/GCV combined with RFH), (b) RFH, (c) HSV-TK/GCV, and (d) phosphate-buffered saline. Data were analyzed by using the Dunnett t test or Kruskal-Wallis test. Results For in vitro experiments, the cell proliferation assay showed significantly diminished viable cells with combination therapy (mean, 0.56; 95% confidence interval [CI]: 0.44, 0.68) versus RFH (mean, 0.89; 95% CI: 0.82, 0.97), HSV-TK/GCV (mean, 0.71; 95% CI: 0.56, 0.86), and phosphate-buffered saline (mean, 1; 95% CI: 1, 1) (P < .05 for all). For in vivo experiments, optical imaging showed significantly decreased relative bioluminescence signal with combination therapy (mean, 0.71 [95% CI: 0.03, 1.39] in mice; 1.29 [95% CI: 0.51, 2.06] in rats) compared with RFH (mean, 2.66 [95% CI: 1.73, 3.59] in mice; 2.26 [95% CI: 1.51, 3.01] in rats), HSV-TK/GCV (mean, 1.37 [95% CI: 0.65, 2.08] in mice; 1.76 [95% CI: 1.20, 2.31] in rats), and phosphate-buffered saline (mean, 3.07 [95% CI: 2.50, 3.65] in mice; 2.94 [95% CI: 2.29, 3.58] in rats) (P < .001 for all). US showed that the smallest relative tumor volumes occurred with combination therapy (mean, 0.60; 95% CI: 0.15, 1.05) versus RFH (mean, 2.43; 95% CI: 1.80, 3.06), HSV-TK/GCV (mean, 1.32; 95% CI: 0.75, 1.89), and phosphate-buffered saline (mean, 2.56; 95% CI: 1.75, 3.38) (P < .05 for all) in the mouse subcutaneous model. Conclusion Intratumoral radiofrequency hyperthermia-enhanced herpes simplex virus thymidine kinase and ganciclovir gene therapy for non-small-cell lung cancer is feasible and can be guided by molecular imaging. © RSNA, 2018.

Noninvasive Theranostic Imaging of HSV-TK/GCV Suicide Gene Therapy in Liver Cancer by Folate-Targeted Quantum Dot-Based Liposomes.

Real-time Visualizing and Tracing of HSV-TK/GCV Suicide Gene Therapy by Near-Infrared Fluorescent Quantum Dots.

Monitoring HSV-TK/ganciclovir Cancer Suicide Gene Therapy Using CdTe/CdS Core/shell Quantum Dots

Cholangiocarcinoma: molecular imaging-guided radiofrequency hyperthermia-enhanced intratumoral herpes simplex virus thymidine kinase gene therapy.

Combined Treatment of Cholangiocarcinoma with Interventional Radiofrequency Hyperthermia and Heat Shock Protein Promoter-Mediated HSV-TK Gene Therapy.

Assessment of therapeutic efficacy of liposomal nanoparticles mediated gene delivery by molecular imaging for cancer therapy.

Abstract No. 576 Orthotopic Ovarian Cancer: Molecular Imaging-Monitored Radiofrequency Hyperthermia-Enhanced Intratumoral Herpes Simplex Virus-Thymidine Kinase (HSV-TK) Gene Therapy

Novel Dual-Function Near-Infrared II Fluorescence and PET Probe for Tumor Delineation and Image-Guided Surgery.

Intrabiliary Radiofrequency Heating-Enhanced Direct Intratumoral GFP/HSV-TK Gene Therapy of Cholangiocarcinoma: A Preclinical Study on Mice and Pigs

Non-Small-Cell Lung Cancer: Feasibility of Intratumoral Radiofrequency Hyperthermia-enhanced Herpes Simplex Virus Thymidine Kinase Gene Therapy

In vivo Imaging-Guided Nanoplatform for Tumor Targeting Delivery and Combined Chemo-, Gene- and Photothermal Therapy.

In Vivo Cancer Targeting and Imaging-Guided Surgery with Near Infrared-Emitting Quantum Dot Bioconjugates

Folate Receptor-Targeted and Cathepsin B-Activatable Nanoprobe for in Situ Therapeutic Monitoring of Photosensitive Cell Death

Tryptophan-sorbitol based carbon quantum dots for theranostics against hepatocellular carcinoma

DNA-Functionalized Liposomes In Vivo Fusion for NIR-II/MRI Guided Pretargeted Ferroptosis Therapy of Metastatic Breast Cancer

Intrathecal Delivery Of Folate Conjugated Near-Infrared Quantum Dots For Targeted In Vivo Imaging Of Gliomas In Mice Brains

Molecularly Near-Infrared Fluorescent Theranostics for in Vivo Tracking Tumor-Specific Chemotherapy

Cancer-targeted Nucleic Acid Delivery and Quantum Dot Imaging Using EGF Receptor Aptamer-conjugated Lipid Nanoparticles

A cancer-targeted glutathione-gated probe for self-sufficient ST/CDT combination therapy and FRET-based miRNA imaging

Folic Acid-Conjugated Silica-Coated Gold Nanorods and Quantum Dots for Dual-Modality CT and Fluorescence Imaging and Photothermal Therapy.

In Vivo Computed Tomography/Photoacoustic Imaging and NIR-Triggered Chemo-Photothermal Combined Therapy Based on a Gold Nanostar-, Mesoporous Silica-, and Thermosensitive Liposome-Composited Nanoprobe.